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Abstract
Objectives Rapid eye movement behaviour disorder (RBD) is
a parasomnia in which there is loss of muscle atonia during
rapid eye movement (REM) sleep, resulting in dream enact-
ment. The aims of this study were to determine the prevalence
of obstructive sleep apnoea (OSA) in RBD patients and deter-
mine whether continuous positive airway pressure (CPAP)
therapy improved RBD symptoms in patients with concomi-
tant RBD and OSA.
Methods A questionnaire was mailed to 120 patients identi-
fied from a tertiary sleep centre with RBD meeting full
International Classification for Sleep Disorders-3 (ICSD-3)
criteria. Patients were diagnosed as having OSA if they had
an apnoea-hypopnea index (AHI) ≥ 5. The questionnaire fo-
cused on CPAP-use, compliance and complications. Standard
statistical analysis was undertaken using SPSS (v.21, IBM).
Results One hundred and seven of the potential participants
(89.2%) had an OSA diagnosis. Out of 72 who responded to
the questionnaire, (60%) 27 patients were using CPAP thera-
py. CPAP therapy improved RBD symptoms in 45.8% of this
group. Despite this positive response to treatment in nearly
half of CPAP-users, there was no significant difference in
subjective or objective CPAP compliance between those
who reported RBD improvement and those who did not.
Subjective compliance with CPAP was over-reported, with
mean usage being 7.17 ± 1.7 h per night compared to objective
mean compliance of 5.71 ± 1.7.
Conclusions OSA is a very common co-morbidity of RBD.
CPAP therapy might improve self-reported RBD symptoms
further, in addition to standard RBD treatment. However, fur-
ther research into its topic is necessary.
Keywords REMbehaviour disorder . Sleep apnoea .
Sleep-disordered breathing . Continuous positive airway
pressure
Introduction
Rapid eye movement (REM) behaviour disorder (RBD) is a
parasomnia characterised by loss of muscle atonia during
REM sleep, resulting in excess motor activity [1] and dream
enactment (e.g. kicking, punching, shouting, falling out of bed)
[2]. These behaviours lead to interrupted sleep as well as injury
to the person and/or their bed partner [3]. Poor sleep quality can
create an adverse impact on performance at work, and the vio-
lent behaviours during sleep can negatively affect relationships.
The prevalence of this condition is estimated to be up to
2% in the elderly population, and even higher in individ-
uals with neuropathological disorders such as Parkinson’s
disease (PD), dementia, oligopontocerebellar degeneration
and subarachnoid haemorrhage [4, 5]. RBD is most com-
mon in males over the age of 50 years [3] and requires
overnight video polysomnography (vPSG) to confirm di-
agnosis as well as exclude other sleep disorders such as
obstructive sleep apnoea (OSA) [6].
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There are two forms of RBD; idiopathic or secondary to
neurological pathology such as narcolepsy, multiple sclerosis,
brain injury or neurodegeneration. RBD is also recognised as
a side effect of certain medications, such as SSRIs, and has
been associated with post-traumatic stress disorder [3].
BDream-enacting^ behaviours are also known to occur in pa-
tients with severe OSA [2, 7]. Almost two-thirds of patients
originally diagnosed with idiopathic RBD develop dementia
and/or PD later in life; therefore, correct diagnosis of RBD is
essential to ensure appropriate monitoring, intervention and
treatment [2, 8].
Currently, the treatments of choice for RBD are clonaze-
pam and melatonin. However, clonazepam should be used
cautiously in patients with concomitant OSA, dementia and
gait disorders due to side effects which include early morning
motor incoordination, memory dysfunction and increased risk
of falling and decreased respiratory tone [9]. Melatonin has
been shown to be beneficial in some patients, either as single
therapy or as an add-on to clonazepam due to minimal side-
effects, no tolerance, dependency, nor hangover effect the fol-
lowing morning [10, 11].
OSA is the cessation of airflow during sleep for at least 10 s
accompanied by continued effort to overcome upper airway
obstruction [2, 4, 12]. Typical symptoms of OSA include ex-
cessive daytime sleepiness, unrefreshing sleep and snoring.
OSA has been associated with obesity [13], hypertension
[14], cardiovascular events, morbidity, stroke [15, 16] and
traffic accidents [17]. The prevalence of OSA has increased
considerably in so-called first world countries. Mild
(15 < AHI ≥ 5) OSA is estimated to affect up to 34.1% men
and 37.4% women, whereas moderate to severe OSA
(AHI ≥ 15) affects 49.7 and 23.4% of men and women, re-
spectively [18]. Moderate to severe OSA is usually treated
with continuous positive airway pressure (CPAP) which
splints the upper airway open, thereby eliminating hypoxia
and reducing sleep fragmentation [12].
Despite a plethora of research into RBD and OSA as dis-
tinct disorders, there is little literature on the coexistence of
RBD and OSA. One study reported a number of patients with
OSA experiencing similar behaviours to those seen in RBD at
the termination of apnoeic events, suggesting that OSA can
sometimes mimic RBD. These patients’ RBD-like symptoms
were abolished once CPAP was commenced as treatment for
their OSA [2]. A second study found that apnoeas appeared to
be less severe in patients with concomitant RBD. The authors
postulated that this could have been due to enhanced EMG
tone in REM, resulting in increased pharyngeal tone, thereby
reducing the number of apnoeas and hypopnoeas in this stage
of sleep [4].
The aim of this study was to determine the prevalence of
OSA in patients with RBD. We hypothesised that CPAP treat-
ment would improve self-reported RBD symptoms in patients
with concomitant RBD and OSA.
Methods
A questionnaire-based study was undertaken in 120 RBD pa-
tients diagnosed and treated at a single tertiary sleep centre
between the years 2000–2016. Potential participants were re-
cruited from an existing cohort of RBD patients diagnosed at
the Department of Sleep Medicine, Royal Infirmary of
Edinburgh.
All patients were sent an anonymised questionnaire with a
cover letter to explain the study. A self-addressed stamped
return envelope was also enclosed. A second mail-out was
undertaken 4 weeks later to those who had not returned the
questionnaire, in order to enrich the return rate.
The questionnaire was designed to focus on areas previous-
ly described, validated and published byWhite et al. [19] with
special emphasis placed on CPAP use including compliance
and complications.
All patients included in this study had been assessed and
investigated clinically by the authors (IM, RLR) and diag-
nosed in accordance with either the ICSD-2 or ICSD-3 criteria
[20]. Overnight video PSG (vPSG), scored according to
criteria, used by Montplaisir el al. [21] with additional self-
report of dream re-enactment was used to confirm the diagno-
sis of REM sleep without atonia (RSWA). Inclusion in this
study required phasic chin EMG signal during REM sleep at
least twice the background activity or greater than 10 μV, for
50% or more of the duration of the epoch. Phasic EMG den-
sity was defined as the percentage of 2 s mini epochs with
phasic twitches, with the amplitude more than four times that
of the background EMG activity. Patients were excluded from
the study if their excess EMG activity was concurrent with
respiratory events and snoring. Patients were also excluded if
they had a diagnosis of concurrent epilepsy, sleep-related
movement disorders or arousal disorders. Diagnosis of con-
comitant OSAwas confirmed with either an inpatient noctur-
nal vPSG study or with a home study enlisting a portable
monitoring device. Time of diagnosis of both conditions var-
ied in different patients. In many cases, OSA and RBD diag-
nosis were made at the same time during a vPSG. However, in
some individuals, RBD and OSA developed independently of
each other and were diagnosed using two separate studies.
Ethical approval was not deemed necessary by the local
research committee, and consent to participate was implied
if the patients returned the questionnaire. All research was
carried out in accordance with the Helsinki criteria [22].
Statistical analysis was undertaken using SPSS (v. 21
IBM). The chi-square test and Fisher’s exact test were used
for discrete variables. The Student t test and Mann-WhitneyU
test were used for continuous variables. Results are reported as
mean ± standard deviation for normally distributed data and
median with interquartile range (IQR 25–75%) for non-
parametrically distributed data. Statistical significance was
taken at p < 0.05, and all tests were two-tailed.
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Results
Of the 120 patients included in the study, 102 (85%) were
male and 18 (15%) were female. The mean age of the subjects
at the time of the study was 57 ± 15 years with an age range of
23 to 85 years (the 23-year-old man had a concurrent diagno-
sis of post-traumatic stress disorder (PTSD)).
Seventy-two (60%) patients responded to the question-
naire; 61 (84.7%) males and 11 (15.3%) females. Of the 48
non-responders, 41 (85.4%) were male and 7 (14.6%) were
female. Of those who did not respond, one was deceased and
ten had an incorrect address. Patients were significantly more
likely to reply to the questionnaire if they were married or had
a partner (p < 0.0001) and if they were over the age of 50 years
(p < 0.0001). Mean age of responders was 61.4 ± 12.2 years
compared to non-responders, who had a mean age of
50.69 ± 16.6 years (p < 0.0001).
For the purpose of this study, patients were defined as hav-
ing OSA meeting treatment guidelines (SIGN) if they had an
AHI of ≥ 5 per hour [18]. We further classified participants as
mild/moderate OSA (AHI ≥5 < 15) and moderate-severe OSA
(AHI ≥ 15) for detailed analysis. Table 1 shows characteristics
of patients with and without OSA in the group of RBD pa-
tients as a whole. Patients with concomitant RBD and OSA
were significantly more likely to be male (p = 0.004).
CPAP treatment
Twenty-seven of the 72 patients (37.5%) who responded to
the questionnaire were using CPAP. None of the responders
had been referred for surgery or construction of a mandibular
repositioning device for their OSA. Most users of CPAP were
male (25 men vs. 2 women) and 11 out of 24 patients
(45.8%—response not given by three participants) reported
improvement in their RBD symptoms as a result.
Table 2 shows data for AHI, self-reported average hours of
use of CPAP, Epworth sleepiness scale (ESS) at outset of treat-
ment and RBD improvement with CPAP. Apart from AHI at
baseline, there was no significant difference between the groups.
Average hours of self-reported use of CPAP per night were
7.17 ± 1.7 h (n = 18) compared to objective CPAP use per
night of 5.71 ± 1.7 h (n = 15). Themajority of responders were
married or in a relationship. Over half of patients treated with
CPAP experienced difficulties when using the device includ-
ing the following: noisiness (n = 1), air leak/poor fit (n = 8),
discomfort (n = 1), dry throat (n = 1), a suffocating feeling
(n = 1), facial sores (n = 2) and cuts on the nose (n = 2).
Almost half (45.8%) of the CPAP users noted an improve-
ment in their RBD symptoms with the use of the CPAP ma-
chine. There was no significant difference in self-reported or
objective CPAP compliance between individuals who report-
ed RBD improvement and those who did not. Self-reported
CPAP compliance was 6.72 ± 1.48 h/night in individuals who
experienced improved RBD symptoms, compared to
7.58 ± 2 h/night for those who did not (p = 0.32). For objective
compliance, mean hours/night were 5.16 ± 1.52 compared to
5.7 ± 3.43, respectively (p = 0.73). OSA severity
(mild/moderate vs. moderate-severe) also did not influence
RBD response to CPAP (p = 0.42). Individuals reporting im-
proved RBD on CPAP demonstrated a non-significantly
higher ESS at baseline than those who did not experience
RBD improvement (10.5 ± 5.16 vs. 7.23 ± 4.24, p = 0.11),
suggestive of a worse baseline sleep quality.
Medications
Of the 72 responders, 38 (54.3%) were taking clonazepam or
melatonin for their RBD at the time of the study. Thirty-five
(87.5%) of these patients weremarried or living with a partner.
Thirty-one patients were taking clonazepam alone, and two
were taking melatonin alone, with further five patients taking
both medications together. Average dose of each treatment
and the response to treatment is shown in Table 3.
Self-reported compliance with medication was not signifi-
cantly different (p = 0.74) in those using CPAP compared to
non-users of CPAP. Of the 11 CPAP-users who answered this
question, ten took their medication 7 days a week (90.9%),
compared to 23 of 26 non-CPAP users (88.5%). Reasons for
not taking medication everyday included the following: not
wanting to depend on medication, symptoms reducing in fre-
quency or severity and being advised by their GP not to take the
medication(s) everyday. Thirty-two of 34 (94%) patients with a
Table 1 Characteristics of
RBD + OSA (AHI ≥ 5 ≤ 15),
RBD + OSA (AHI ≥ 15) and
RBD without OSA patients
(n = 120)
RBD + OSA
(AHI ≥ 5 < 15)
RBD + OSA
(AHI ≥ 15)
RBD without OSA p value
M:F ratio 30:12 62:3 10:3 0.004
ESS (n/24) 7.32 ± 5.23 9.07 ± 5.38 9.54 ± 7.68 0.25
BMI (kg/m2) 28.89 ± 6.83 30.63 ± 6.11 27.12 ± 2.86 0.12
Age at diagnosis 51.71 ± 15.8 56.24 ± 13.36 50.1 ± 16 0.2
AHI/h 10.55 ± 2.74 36.11 ± 22.9 3.62 ± 1.1 < 0.0001
Percentage of the sample 35 54.2 10.8 –
Characteristics of patients with and without OSA in the group of RBD patients as a whole
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spouse/partner who responded to the question took their med-
ication 7 days per week (p < 0.0001). Of the 12 patients who
returned the questionnaire and were single, only four responded
to the question, all stating that they complied 7 days a week.
Lifestyle changes
Fifteen CPAP users were advised to make lifestyle changes by
their doctor, whereas 17 patients who did not use CPAP were
advised to make lifestyle changes. Lifestyle changes sug-
gested ranged from reducing alcohol and caffeine intake to
using a bed guard and increasing exercise. Half (50%) of the
responding CPAP users (n = 7) and nine of the responders not
using CPAP (52.9%) noticed an improvement (reduction in
frequency and severity) in their RBD symptoms after making
these lifestyle changes. The majority of patients (52%, n = 39)
were not given specific lifestyle recommendations. Caffeine
reduction was the most commonly suggested change (22.7%).
Discussion
This is the first study to specifically explore the effects of
treating sleep disordered breathing (SDB) in RBD. There have
been few papers previously published discussing concomitant
RBD and OSA. Response to the questionnaire was excellent,
with 60% of patients responding. Of 120 patients, 89.2% had
RBD plus an AHI ≥ 5/h suggesting that RBD/OSA is com-
mon, particularly in older populations, irrespective of BMI.
Patients with concomitant RBD and OSA were significantly
more likely to be male (p = 0.004). A study from the USA
showed OSA prevalence in RBD to be 34% [23], and another
case series from Hong Kong reported the prevalence to be
61% [24]. Our study results are similar to these figures.
However, the prevalence of OSA in RBD may have been
underestimated as these aforementioned studies used an
AHI ≥ 10/h to diagnose OSA and this study used AHI ≥ 15.
If a cutoff of AHI ≥ 10/h is applied to our study, the prevalence
amongst our responding RBD cohort rises to 75% (n = 120).
Patients in this study reported relatively high compliance
with CPAP treatment compared to other studies [4, 25], with
average use of 7.17 ± 1.7 and 5.71 ± 1.7 h per night in sub-
jective and objective assessment, respectively. All patients
attended a tertiary sleep centre, and it is possible that they
may have been exposed to multiple treatment regimens before
and therefore may have understood the benefits of treatment
better. Studies have shown those who adhere to one treatment
are more likely to adhere to others [26]. The patients in this
Table 2 Characteristics of
CPAP-users vs. non-CPAP users
in questionnaire responders
CPAP-user
(n = 27)
Non-CPAP user
(n = 45)
p value
Male (n) 25 (92.6%) 36 (80%) 0.15
Age (years) 57.37 ± 10.78 57.75 ± 12.87 0.89
BMI (kg/m2) 30.24 ± 24.89 28.65 ± 4.61 0.16
ESS (n/24) 8.52 ± 4.88 6.59 ± 5.72 0.16
AHI/h 30.24 ± 24.89 16.78 ± 16.06 0.02
Live with partner (n) 23 (85.2%) 37 (82.2%) 0.7
Self-reported CPAP usage (hours) 7.17 ± 1.7 – –
Objective CPAP usage (hours) 5.71 ± 1.7
RBD improvement with CPAP 11/27 (45.8%) – –
Data for AHI, hours of CPAP use, Epworth Sleepiness Score (ESS) at outset of treatment and RBD improvement
with CPAP
Table 3 Medication use for RBD
in questionnaire responders
(n = 72)
CPAP-user Non-CPAP user p value
Clonazepam (n = 31) 6 24 0.05
Dose clonazepam (mg) 2.32 ± 1.77 1.36 ± 1.24 0.16
RBD improvement with clonazepam 5/6 19/24 1.0
Melatonin (n = 2) 1 1 0.44
Dose melatonin (mg) 4.25 ± 2.06 2.33 ± 0.57 0.3
RBD improvement with melatonin 1/1 1/1 1.0
Clonazepam + melatonin (n = 5) 3 2 0.3
RBD improvement with clonazepam + melatonin 3/3 2/2 1
Average dose of each treatment medication and the response to treatment
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study reported regular use of their current RBD medications;
this medication compliance is reflected in the high-CPAP
compliance that was demonstrated objectively. The results
also point to the variability of RBD and its expression.
Almost half (45.8%) of patients on CPAP noticed an im-
provement in their RBD symptoms with CPAP treatment
supporting our hypothesis that CPAP may improve RBD con-
comitant with OSA. However, there was no significant differ-
ence in the subjective or objective compliance of individuals
who experienced RBD improvement on CPAP therapy com-
pared to those who did not. This suggests that degree of CPAP
compliance does not affect severity of RBD symptoms.
Iranzo et al. reported that severe OSA can imitate RBD
symptoms and that this phenomenon can be successfully treat-
ed by CPAP [2]. This suggests true RBD could be exacerbated
by OSA. With most of the RBD behaviours occurring at the
termination of apnoeic events [2], if the apnoeas in those with
OSA are treated, then the abnormal dream enactment behav-
iours associated with RBD may not occur or may occur with
less severity or frequency. The RBD symptom improvements
reported by approximately half of the responders may there-
fore have been due to a reduction in pseudo-RBD behaviours
associated with concomitant OSA.
Another reason CPAP may benefit RBD in patients with
concomitant OSA is by reducing sleep fragmentation [12].
Theoretically, OSA could be causing pseudo-RBD symptoms
in addition to true RBD or OSA could be exacerbating RBD
through sleep fragmentation, arousals and sleep disruption [2].
It is therefore feasible that patients using CPAP would report a
decrease in RBD events, as they are unable to distinguish
which of their symptoms are caused by RBD and which
symptoms are the result of OSA-related pseudo-RBD. No
study has ever investigated spectral densities of REM EEG
in RBD, but there is evidence that REM EEG activity is de-
creased in OSA [27] just as there is evidence supporting
changes in EEG density in slow-wave sleep disorders [27].
Interestingly, CPAP compliance was not statistically differ-
ent between individuals with concomitant OSAwho reported
improved RBD with CPAP therapy and those who did not.
This suggests that the extent of CPAP use does not affect RBD
symptom severity, and therefore, other factors must be con-
sidered which may positively influence RBD expression.
While we report that OSA severity (mild/moderate vs. severe)
does not affect RBD response to CPAP therapy, the OSA
phenotype may influence treatment response. For example,
individuals who suffer from REM-dependent OSA (apnoeas
and hypopnoeas present during REM sleep) [28] may experi-
ence a subjective improvement in RBD symptoms on CPAP
treatment compared to individuals with position-dependent
OSA (apnoeas and hypopnoeas present in supine position).
REM-dependent OSA results in disturbed REM sleep, which
in turn might exacerbate RBD; therefore, improved REM
sleep with CPAP use might act to decrease RBD behaviours.
There are no reports in the literature exploring this relationship
between OSA phenotype, RBD and CPAP-response, demon-
strating a need for further research.
CPAP therapy can create REM rebound when treatment
commences [5], ultimately increasing the number of RBD
episodes experienced by the patient. Although this phenome-
non is generally short-lived, it is important that patients are
informed of this potential side effect to ensure they persevere
with CPAP treatment.
The majority of patients diagnosed with RBD are pre-
scribed pharmacological treatment to treat the disorder. In
our study, over half of patients were currently taking either
one of or a combination of clonazepam and melatonin. Due to
the respiratory-depressive effects of benzodiazepines on mus-
cle tone [29], clonazepam may aggravate symptoms of OSA,
subsequently increasing a patient’s AHI. An increase in OSA
symptoms may cause a secondary increase in RBD symptoms
due to sleep fragmentation.
One of the limitations of this study was the use of a self-
reporting questionnaire with its attendant biases. For future
studies, it would be beneficial to create a standard instrument
from existing questionnaires to be used longitudinally during
a set period of time from CPAP commencement. Patients
responding to our questionnaire tended to be older with a
spouse/partner. This may also have increased the likelihood
of adherence to therapy, as it has been shown that marital
status contributes to therapy adherence [30, 31]. Similarly,
individuals who experienced a positive response to CPAP
may have been more likely to respond to the questionnaire
than those who found no benefit.
We explored the effect of three treatment options on RBD
symptoms. Many of the individuals in our cohort were on
several treatments and may have been unable to determine
which improved their RBD. Further investigation between
the interactions of different RBD treatments is required.
The study sample size, though small, is large for a reason-
ably uncommon condition such as RBD. In the future, a
follow-up vPSG study for all patients, in order to objectively
quantify changes in RSWA, would be ideal. This would elim-
inate the inevitable recall bias of questionnaire methodology
regarding improvement in RBD symptoms, especially given
the 17-year recall period.
The level of detail regarding changes to RBD symptoms
was limited by the phrasing of questions within the question-
naire. Therefore, data regarding worsening of RBD symptoms
and the nature of RBD improvement (for example, severity or
frequency of RBD behaviours) was not available for analysis
and the potential disadvantages of CPAP use in RBD patients
cannot be further explored in this study.
The high prevalence of concomitant OSA in RBD estab-
lishes that it occurs commonly. CPAP therapy is safe and
effective in the context of RBD and sleep-disordered breath-
ing and may enhance the effects of (and therefore reduce)
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medication requirements in these patients. If OSA is signifi-
cant or contributing to additional nocturnal symptoms such as
snoring and daytime sleepiness, CPAP can be trialled safely.
Patients diagnosed with concomitant RBD and OSA should
be given the opportunity to undergo a trial CPAP if clinically
indicated. This may improve overall sleep quality and health.
However, further research in this area is necessary in order to
establish any clear effects of CPAP treatment on RBD per se.
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